REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML

被引：0

作者：

Tiribelli, M. ^{[1
]}

Bonifacio, M. ^{[2
]}

Binotto, G. ^{[3
]}

Iurlo, A. ^{[4
,5
]}

Cibien, F. ^{[6
]}

Maino, E. ^{[7
]}

Guella, A. ^{[8
]}

Festini, G. ^{[9
]}

Minotto, C. ^{[10
]}

De Biasi, E. ^{[11
]}

De Marchi, F. ^{[12
]}

Scaffidi, L. ^{[2
]}

Frison, L. ^{[13
]}

Bucelli, C. ^{[4
,5
]}

Medeot, M. ^{[1
]}

Calistri, E. ^{[14
]}

Sancetta, R. ^{[7
]}

Stulle, M. ^{[9
]}

Krampera, M. ^{[2
]}

Gherlinzoni, F. ^{[15
]}

Semenzato, G. ^{[3
]}

Ambrosetti, A. ^{[2
]}

Fanin, R. ^{[1
]}

机构：

[1] Azienda Osped Univ Udine, Div Hematol & BMT, Udine, Italy

[2] Univ Verona, Sect Hematol, Dept Med, Verona, Italy

[3] Univ Padua, Hematol Sect, Dept Med, Sch Med, Padua, Italy

[4] IRCCS Ca Granda Maggiore Policlin Hosp Fdn, Oncohematol Div, Milan, Italy

[5] Univ Milan, Milan, Italy

[6] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[7] DellAngelo Hosp, Hematol Unit, Venice, Italy

[8] Santa Chiara Hosp, Hematol Unit, Trento, Italy

[9] AOU Ospedali Riuniti, Div Clin Hematol, Trieste, Italy

[10] ULSS 13, Dept Med Special, Oncol & Oncohematol Unit, Venice, Italy

[11] P Cosma Hosp, Hematol Unit, Padua, Italy

[12] Azienda Osped Univ Udine, Div Hematol & BMT, Udine, Italy

[13] HemPadua Univ, Sch Med, Dept Med, Dept Med,Hematol Sect, Padua, Italy

[14] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[15] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P612

引用

页码：237 / 238

页数：2

共 50 条

[21] PREDICTIVE FACTORS OF STABLE DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CML PATIENTS TREATED WITH DASATINIB OR NILOTINIB AFTER IMATINIB FAILURE
Bonifacio, M.
Binotto, G.
Tiribelli, M.
Scaffidi, L.
Iurlo, A.
Cibien, F.
Maino, E.
Guella, A.
Festini, G.
Minotto, C.
De Biasi, E.
Frison, L.
De Marchi, F.
Medeot, M.
Bucelli, C.
Calistri, E.
Stulle, M.
Gherlinzoni, F.
Cortelezzi, A.
Fanin, R.
Semenzato, G.
Krampera, M.
Pizzolo, G.
Ambrosetti, A.
HAEMATOLOGICA, 2016, 101 : 735 - 735
[22] Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib
Latagliata, Roberto
Breccia, Massimo
Stagno, Fabio
Luciano, Luigiana
Gozzini, Antonella
Castagnetti, Fausto
Annunziata, Mario
De Matteis, Silvia
Albano, Francesco
Ulisciani, Stefano
Pregno, Patrizia
Porrini, Raffaele
Abruzzese, Elisabetta
Martino, Bruno
Tiribelli, Mario
Musto, Pellegrino
Avanzini, Paolo
Rossi, Antonella Russo
Sica, Simona
Vitolo, Umberto
Montefusco, Enrico
Cambrin, Giovanna Rege
Ferrara, Felicetto
Rosti, Gianantonio
Santini, Valeria
Pane, Fabrizio
Di Raimondo, Francesco
Alimena, Giuliana
BLOOD, 2009, 114 (22) : 871 - 871
[23] Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
Usala, Emilio
CLINICAL MANAGEMENT ISSUES, 2011, 5 : 27 - 30
[24] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
F J Giles
E Abruzzese
G Rosti
D-W Kim
R Bhatia
A Bosly
S Goldberg
G L S Kam
M Jagasia
W Mendrek
T Fischer
T Facon
U Dünzinger
D Marin
M C Mueller
Y Shou
N J Gallagher
R A Larson
F-X Mahon
M Baccarani
J Cortes
H M Kantarjian
Leukemia, 2010, 24 : 1299 - 1301
[25] Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Giles, F. J.
Abruzzese, E.
Rosti, G.
Kim, D-W
Bhatia, R.
Bosly, A.
Goldberg, S.
Kam, G. L. S.
Jagasia, M.
Mendrek, W.
Fischer, T.
Facon, T.
Duenzinger, U.
Marin, D.
Mueller, M. C.
Shou, Y.
Gallagher, N. J.
Larson, R. A.
Mahon, F-X
Baccarani, M.
Cortes, J.
Kantarjian, H. M.
LEUKEMIA, 2010, 24 (07) : 1299 - 1301
[26] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
Giles, Francis J.
le Coutre, Phillip
Bhalla, Kapil N.
Ossenkoppele, Gert
Alimena, Giuliana
Haque, Ariful
Gallagher, Neil
Kantarjian, Hagop M.
BLOOD, 2007, 110 (11) : 311A - 312A
[27] Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
Massimo Breccia
Elisabetta Abruzzese
Fausto Castagnetti
Massimiliano Bonifacio
Domenica Gangemi
Federica Sorà
Alessandra Iurlo
Luigiana Luciano
Antonella Gozzini
Massimo Gentile
Monica Bocchia
Debora Luzi
Alessandro Maggi
Nicola Sgherza
Alessandro Isidori
Monica Crugnola
Patrizia Pregno
Anna Rita Scortechini
Isabella Capodanno
Michele Pizzuti
Robin Foà
Annals of Hematology, 2018, 97 : 1577 - 1580
[28] Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
Breccia, Massimo
Abruzzese, Elisabetta
Castagnetti, Fausto
Bonifacio, Massimiliano
Gangemi, Domenica
Sora, Federica
Iurlo, Alessandra
Luciano, Luigiana
Gozzini, Antonella
Gentile, Massimo
Bocchia, Monica
Luzi, Debora
Maggi, Alessandro
Sgherza, Nicola
Isidori, Alessandro
Crugnola, Monica
Pregno, Patrizia
Scortechini, Anna Rita
Capodanno, Isabella
Pizzuti, Michele
Foa, Robin
ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1577 - 1580
[29] Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase
Takahashi, Koichi
Kantarjian, Hagop M.
Jain, Preetesh
Jabbour, Elias
Wierda, William
Pemmaraju, Naveen
Ferrajoli, Alessandra
Dellasala, Sara E.
Pierce, Sherry
Verstovsek, Srdan
Ravandi, Farhad
O'Brien, Susan
Cortes, Jorge E.
BLOOD, 2014, 124 (21)
[30] Compassionate use experience with dasatinib therapy in patients after imatinib and/or nilotinib failure
Gunawardena, Bettina A.
Schlief, Sarah
Dempke, Wolfram
Wnterhalter, Bernd
BLOOD, 2007, 110 (11) : 212B - 212B

← 1 2 3 4 5 →